MedTrace Logo

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00676052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2017-10-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK233705 12.5mcg

Once daily via dry powder inhaler

DRUG

GSK233705 25mcg

once daily via dry powder inhaler

DRUG

GSK233705 50mcg

Once daily via dry powder inhaler

DRUG

GSK233705 100mcg

Once daily via dry powder inhaler

DRUG

GSK233705 200mcg

Once daily via dry powder inhaler

DRUG

Placebo

Once daily via dry powder imhaler

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-16
Primary Completion
2008-12-22
Completion
2008-12-22

Countries

  • United States
  • Argentina
  • Bulgaria
  • Canada
  • Chile
  • Germany
  • Hungary
  • Netherlands
  • Philippines
  • Romania
  • South Africa
  • South Korea
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676052 on ClinicalTrials.gov